Innovation

Group leader: Julio Arrizabalaga Aguirreazaldegui, M.D., Ph.D.

Biodonostia HRI - Donostialdea IHO julio.arrizabalaga@osakidetza.eus

Strategic Objectives

The Innovation Group comes under the Bioengineering Area, one of the seven research areas at the BioDonostia HRI. It is made up of a group of associated researchers comprising representatives from different technological organisations, collaborating in a subject field that is not included in the priority areas of research, but whose development can lead to inclusion in any of the established groups or areas (Consolidated or Emerging).

The inter-disciplinary and multi-institutional collaboration model at the BioDonostia HRI is evident in this group, which promotes translational health research with the purpose of improving people’s quality of life.

The main focus of research are micro and nano biotechnologies, biomaterials, molecular imaging, ICT and e-health, always aimed at innovation.

This group began with the 2009 Strategic Health Action plan in the RETICS [Cooperative Health Research Thematics Networks] sub-programme, the funding of which boosted the creation of the Institute’s Innovation Unit, whose purpose was to generate innovation in the non-pharmacological field of medical and health technologies as regards equipment, appliances, reactives, materials and ICT in health.

The drive given to collaborative translational research on a national and international level from this Group has led to a third of the Institute’s projects being carried out with a technology partner.

 

 

Team Members

Name Surname Center E-mail
Arantza Abad Alba Biodonostia HRI arantza.abad@biodonostia.org
Sandra Ahedo González Zabaleta Biodonostia HRI sandra.ahedo@biodonostia.org
Amaia Albandoz Arranz BIOEF amaia@bioef.org
Olatz Arrizabalaga Garde Biodonostia HRI olatz.arrizabalaga@biodonostia.org
Maria Isabel Arzamendi Sesé Biodonostia HRI mariaisabel.arzamendisese@osakidetza.eus
Susana Belaustegi Ituarte BIOEF
Pablo Casuso Pérez IK4 – Cidetec
Amaia Del Villar Alvarez Biodonostia HRI amaya.delvillar@biodonostia.org
Daniel Dupin IK4 – Cidetec ddupin@cidetec.es
Ainize Iriondo Plaza Biodonostia HRI ainize.iriondoplaza@osakidetza.eus
Ramón Lerchundi Goñi Donostialdea IHO ramon.lerchundigoni@osakidetza.eus
Luis Liz Marzan CIC BiomaGUNE
Iraida Loinaz Bordonabe IK4 – Cidetec iloinaz@cidetec.es
Marco Marradi IK4 – Cidetec mmarradi@cidetec.es
Pablo Martínez-Lage Álvarez CITA-Alzheimer
Joseph Mcintyre Tecnalia joseph.mcintyre@tecnalia.com
Ander Ramos Murguialday Tecnalia ander.ramos@tecnalia.com
Idoia Tolosa Marín IK4 – Cidetec itolosa@cidetec.es

Scientific Output

Originals

Published: 10 / 118

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L, D:A:D study group, Royal Free Hospital Clinic Cohort, INSIGHT study group, SMART study group, ESPRIT study group.

PLoS Med. 2015; 12. FI: 14.429 (Q1).

Subthalamic stimulation modulates cortical motor network activity and synchronization in Parkinson’s disease.

Weiss D, Klotz RG, Rathinaswamy B, Scholten M, Naros G, Ramos-Murguialday A, Bunjes F, Meisner C, Plewnia C, Krueger R, Gharabaghi A.

Brain. 2015; 138: 679-693. FI: 9.196 (Q1).

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin. Infect. Dis. 2015; 60: 1262-1268. FI: 8.886 (Q1).

Design of Stable and Powerful Nanobiocatalysts, Based on Enzyme Laccase Immobilized on Self-Assembled 3D Graphene/Polymer Composite Hydrogels.

Ormategui N, Veloso A, Patricia G, Rodriguez-Couto S, Tomovska R.

ACS Appl. Mater. Interfaces. 2015; 7: 14104-14112. FI: 6.723 (Q1).

Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012).

Monge S, Díez M, Alvarez M, Guillot V, Iribarren JA, Palacios R, Delgado R, Jaén A, Blanco JR, Domingo P, Portilla J, Pérez EMJ, Garcia F, Cohorte de la Red de Investigación en Sida (CoRIS).

Clin. Microbiol. Infect. 2015; 21: 105.e1-5. FI: 5.768 (Q1).

Injectable and Self-Healing Dynamic Hydrogels Based on Metal(I)-Thiolate/Disulfide Exchange as Biomaterials with Tunable Mechanical Properties. Biomacromolecules.

Casuso P, Odriozola I, Perez-San Vicente A, Loinaz I, Cabanero G, Grande HJ, Dupin D.

2015; 16: 3552-3561. FI: 5.750 (Q1).

Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy.

Blanco JR, Jarrin I, Martinez A, Siles E, Larrayoz IM, Cañuelo A, Gutierrez F, Gonzalez-Garcia J, Vidal F, Moreno S, CoRIS-Biobanco.

J Acquir Immune Defic Syndr. 2015; 68: 21-29. FI: 4.556 (Q1).

Enhanced features of Li2CO3 sputtered thin films induced by thickness and annealing time.

Rojo L, Castro-Hurtado I, Morant-Minana MC, Mandayo GG, Castano E.

Crystengcomm. 2015; 17: 1597-1602. FI: 4.034 (Q1).

Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain.

Serrano-Villar S, Sobrino-Vegas P, Monge S, Dronda F, Hernando A, Montero M, Viciana P, Clotet B, Pineda JA, Del Amo J, Moreno S, CoRIS.

J Viral Hepat. 2015; 22: 496-503. FI: 3.909 (Q1).

Mixing the immiscible: blends of dynamic polymer networks.

Martin R, Rekondo A, Ruiz de Luzuriaga A, Santamaria A, Odriozola I.

RSC Adv. 2015; 5: 17514-17518. FI: 3.840 (Q1).

Reviews

Published: 3 / 3

The physics of tobacco mosaic virus and virus-based devices in biotechnology.

Alonso JM, Gorzny ML, Bittner AM.

Trends Biotechnol. 2013; 31: 530-538. FI: 9.660 (Q1).

Brain-computer interfaces in the completely locked-in state and chronic stroke.

Chaudhary U, Birbaumer N, Ramos-Murguialday A.

Prog Brain Res. 2016; 228: 131-161. FI: 2,68 (Q3).

Brain-computer interfaces for communication and rehabilitation.

Chaudhary U, Birbaumer N, Ramos-Murguialday A.

Nature Reviews Neurology. 2016; 12: 513-525. FI: 20,257 (Q1).

Editorials

Published: 0 / 0

Letters

Published: 0 / 0

Others

Published: 0 / 0

Projects

Projects 5 / 5

Nuevas terapias en el cáncer de mama: Caracterización in vivo de la actividad y estructura del receptor de estrógenos bloqueo de VAV-3 y desarrollo de análogos de YC-1V.

Investigador principal: Ander Urruticoechea Ribate. Entidad financiadora: ISCII Instituto de Salud Carlos III. Año inicio: 2014. Año final: 2017.

Línea de fortalecimiento institucional: Institutos de Investigación Sanitaria.

Investigador principal: Julio Arrizabalaga Aguirreazaldegui. Entidad financiadora: ISCII Instituto de Salud Carlos III. Año inicio: 2014. Año final: 2015.

Diseño de un formulario de apoyo en la evaluación de tecnologías sanitarias a nivel de Hospital Universitario Donostia.

Investigador principal: Julio Arrizabalaga Aguirreazaldegui. Entidad financiadora: Hospital Universitario Donostia. Año inicio: 2014. Año final: 2015.

Red transfronteriza de investigación biomédica de los Pirineos – Establecimiento de una red de colaboración estable ente centros de investigación biomédica en el espacio Pirineo.

Investigador principal: Julio Arrizabalaga Aguirreazaldegui. Entidad financiadora: POCTEFA-Interreg IV A. Año inicio: 2012. Año final: 2015.

Caracterización pre-clínica y clínica de un nuevo abordaje terapeútico en cáncer de mama con resistencia adquirida a tratamiento hormonal.

Investigador principal: Ander Urruticoechea Ribate. Entidad financiadora: ISCII Instituto de Salud Carlos III. Año inicio: 2013. Año final: 2015.